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Inadequacy of antiretroviral
drugs dosage adjustment in
HIV patients receiving dialysis
Letter to the Editor: Szczech et al [1] reported an
interesting study in a recent issue of Kidney International.
The authors reported the antiretroviral drugs dosing reg-
imens they observed in their hemodialyzed patients. We
further analyzed these dosing regimens and it appeared
that dosage adjustement were most often inadequate for
those patients with end-stage renal disease.
Table 1. Comparison of antiretroviral dosage reported in Szczech’s
study and available dosing recommendations for hemodialysis
patients [2]
Recommended
Drug N Dosage dosage
Nucleoside reverse transcriptase inhibitors
Abacavira 3 300 to 600 mg/day 1200 mg/day
Didanosine 7 100 to 400 mg/day 50 to 100 mg/day
Lamivudine 36 25 to 300 mg/day 150 mg first dose then
25 to 50 mg/day
Stavudine 33 10 to 40 mg/day 15 to 20 mg/day
Zidovudine 11 100 mg 3 × a week 300 mg/day
to 600 mg/day
Combivir 8
Lamivudine 150 to 450 mg/day 150 mg first dose then
25 to 50 mg/day
Zidovudine 300 to 900 mg/day 300 mg/day
Non-nucleoside reverse transcriptase inhibitors
Efavirenza 13 200 to 600 mg/day 600 mg/day
Nevirapinea 11 200 to 400 mg/day 200 to 400 mg/day
Protease inhibitors
Indinavira 6 1600 to 2400 mg/day 2400 mg/day
Nelfinavira 21 500 to 2500 mg/day 2250 mg/day
Ritonavira 5 200 to 1000 mg/day 1200 mg/day
Saquinavira 2 800 to 3600 mg/day 1800 mg/day
N = Number of patients in Szczech’s study.
Combivir, 1 capsule contains 150 mg lamivudine and 300 mg zidovudine.
aDrug for which dosage adjustment is not necessary in hemodialyzed patients.
We read with great interest Szczech’s article [1], in
which they concluded that antiretroviral medications
were not used at their optimal dose in the human
immunodeficiency virus (HIV) hemodialysis patients
they studied because data on these drugs’ pharmacoki-
netics and dosage adjustment in patients with renal insuf-
ficiency are lacking. However, we would like to outline
that most antiretroviral drugs’ pharmacokinetics have
been studied in patients with renal insufficiency.
Based on those publications and our personal data, we
have recently published precise guidelines on antiretro-
viral drug dosage adjustment in hemodialysis patients [2].
Among the 11 antiretroviral drugs reported in Szczech’s
article, only 1 was administered at the correct dose (nevi-
rapine). The other drugs that should have been prescribed
at their usual dosage were either underdosed (abacavir,
efavirenz, indinavir, nelfinavir, ritonavir, saquinavir) or
overdosed (saquinavir). For the latter, the usual recom-
mended dose for hemodialysis patients is 1800 mg/day
[2]; the dosing range reported by Szczech is 800 to
3600 mg/day. Among the drugs that should have had their
dose adjusted according to the patients’ renal function,
didanosine was clearly overdosed. Stavudine, lamivudine,
and zidovudine administered alone were either under- or
overdosed. Finally, the use of the lamivudine-zidovudine
combination drug Combivir led to a large overdose in
all cases.
Consequently, although we agree that further pharma-
cokinetic, tolerance, and efficacy studies are mandatory
for these patients, dose adjustment recommendations
exist [2] and should already be routinely applied.
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Calcimetic AMG 073 at 50
and 100 mg per day
To the Editor: A comparison of the assessment against
placebo of the calcimimetic AMG 073 at 50 [1] and
